Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin effects on pro-inflammatory T cells and Treg in acute coronary syndrome
2008-007297-38Phase 4Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atorvastatin in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) and coronary arteriosclerosis (2 arms), sponsored by Policlinico Gemelli. Primary endpoints: Change in CD4+CD28null T cell number and function and Change in regulatory T cell (Treg) number and function. Started Dec 2008; status: completed.
02
Drugs
atorvastatin
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2008-007297-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007297-38.